Evidence · Outcomes · Precedents

Successful cases in stem cell & cell therapy

The therapies that worked, and the numbers that got them through FDA review. Use these as precedents when you design endpoints, choose a cell source or plan a customized product.

30FDA-approved successes
9investigational breakthroughs
9backed by randomized trials
38FDA licenses covered (incl. 9 cord blood banks)
Patient or family member? Pick your condition below. If nothing matches, read the plain-language guide before talking to any clinic.

Find by condition

39 of 39 cases shown

Gene-corrected stem cellsFDA-approved

CASGEVY

exagamglogene autotemcel

Sickle cell disease and transfusion-dependent beta-thalassemia (age 2+ since Jul 2026)

29 of 31free of severe sickle cell crises for 12+ months

The patient's own blood stem cells are edited with CRISPR/Cas9 and returned once. 29 of 31 evaluable adults and teens had no severe crises for at least 12 months. In children 5–11, 8 of 8 with sickle cell were crisis-free and 8 of 9 with thalassemia stopped transfusions.

Why it matters: First CRISPR medicine in the US: proof that a fully personalized, edited stem cell product can clear FDA.

Approved
Dec 8, 2023 (SCD); Jan 16, 2024 (TDT); Jul 1, 2026 (age 2+)
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
No boxed warning. Requires chemotherapy conditioning (low blood counts, mouth sores, febrile neutropenia).
FDA: first gene therapies for sickle cell disease ↗
Gene-corrected stem cellsFDA-approved

LYFGENIA

lovotibeglogene autotemcel

Sickle cell disease with a history of vaso-occlusive events (age 12+)

88%complete resolution of vaso-occlusive events (28 of 32), months 6–18

A lentiviral vector adds a working beta-globin gene to the patient's own stem cells. 28 of 32 patients had no vaso-occlusive events between 6 and 18 months after infusion.

Why it matters: Approved the same day as CASGEVY: two engineering routes (gene addition vs editing) for one disease.

Approved
Dec 8, 2023
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
Boxed warning for blood cancer; lifelong monitoring.
FDA: first gene therapies for sickle cell disease ↗
Gene-corrected stem cellsFDA-approved

ZYNTEGLO

betibeglogene autotemcel

Beta-thalassemia needing regular transfusions (adults and children)

89%of 41 patients transfusion-independent for 12+ months

One dose of the patient's own gene-modified stem cells. 89% of 41 patients stopped needing red cell transfusions for at least a year with stable hemoglobin.

Why it matters: First cell-based gene therapy for beta-thalassemia, each dose made from one patient's own marrow.

Approved
Aug 17, 2022
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
No boxed warning; possible blood cancer risk (none seen); monitor 15+ years.
ASCO Post: FDA approves Zynteglo ↗
Gene-corrected stem cellsFDA-approved

SKYSONA

elivaldogene autotemcel

Early active cerebral adrenoleukodystrophy in boys without a matched donor

72% vs 43%alive without major disability at 24 months, treated vs untreated

The boy's own stem cells receive a working ABCD1 gene. At 24 months, 72% of treated boys were alive without major functional disability versus 43% in natural-history patients.

Why it matters: The clearest example of risk emerging years after approval: long-term follow-up matters.

Approved
Sep 16, 2022 (accelerated); restricted Aug 2025
Evidence
Natural-history control
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: blood cancers rose from 3 of 67 to 10 of 67 by July 2025; FDA limited use to boys with no matched donor.
FDA: labeling changes for hematologic malignancy risk ↗
Gene-corrected stem cellsFDA-approved

LENMELDY

atidarsagene autotemcel

Metachromatic leukodystrophy (MLD) in children

100% vs 58%alive at age 6, treated vs untreated (presymptomatic late infantile)

The child's stem cells get a working ARSA gene. Across 37 treated children, severe motor impairment or death fell sharply; 71% walked unaided at age 5 and 85% had normal language and IQ scores.

Why it matters: Works when given before symptoms: makes the case for newborn screening.

Approved
Mar 18, 2024
Evidence
Natural-history control
Cell source
Autologous (patient's own cells)
Safety
No boxed warning; no blood cancers seen. Monitor 15+ years.
FDA: first gene therapy for children with MLD ↗
Gene-corrected stem cellsFDA-approved

WASKYRA

etuvetidigene autotemcel

Wiskott-Aldrich syndrome (age 6 months+, no matched related donor)

−93%severe infections, months 6–18 vs year before treatment

Gene-corrected stem cells from 27 patients. Severe infections fell 93% and moderate-to-severe bleeding fell 60%; most patients were bleed-free at 4 years.

Why it matters: Developed by a non-profit (Fondazione Telethon): an alternative sponsor model for ultra-rare disease.

Approved
Dec 9, 2025
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
No boxed warning reported. Rash, respiratory infection, febrile neutropenia, liver injury.
FDA: first gene therapy for Wiskott-Aldrich syndrome ↗
Gene-corrected stem cellsFDA-approved

KRESLADI

marnetegragene autotemcel

Severe leukocyte adhesion deficiency type I in children without a matched sibling donor

100%survival without transplant at 1 year (9 children; 95% CI 66–100)

Stem cells corrected with the ITGB2 gene. All children enrolled before age 1 were alive past age 2. FDA's accelerated approval rests on restored CD18/CD11a on white cells at 12 months, sustained to 24 months.

Why it matters: Accelerated approval on a biomarker with only 9 patients: a template for ultra-rare indications.

Approved
Mar 26, 2026 (accelerated)
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
No boxed warning reported. Confirmatory evidence required for full approval.
FDA: first gene therapy for LAD-I ↗
Blood & immune rebuildFDA-approved

TREGZI

Orca-T; regulatory T cells with HSPCs and T cells

Adults with blood cancers having matched-donor transplant

78% vs 38%1-year survival free of moderate-to-severe chronic GVHD

A precision-engineered donor graft tested against a standard transplant in 187 adults with acute leukemia or MDS (Precision-T). Chronic GVHD fell from 44% to 13% (HR 0.26); overall survival was 93.9% vs 83.1%, not statistically significant.

Why it matters: Strongest randomized win among stem/progenitor products.

Approved
Jun 30, 2026
Evidence
Randomized
Cell source
Allogeneic (donor cells)
Safety
Warnings: graft failure, GVHD, infusion reactions, secondary cancers. List price $428,000.
CancerNetwork: FDA OKs regulatory T-cell immunotherapy ↗
Blood & immune rebuildFDA-approved

OMISIRGE

omidubicel-onlv

Blood cancers needing cord blood transplant (age 12+); severe aplastic anemia (Dec 2025)

12 vs 22 daysmedian neutrophil recovery vs standard cord blood

Cord blood expanded with nicotinamide, tested against standard cord blood in 125 patients. White cells recovered faster and serious infections by day 100 fell from 60% to 39%.

Why it matters: Expanded cord blood widens donor options for patients without a matched adult donor.

Approved
Apr 17, 2023
Evidence
Randomized
Cell source
Allogeneic (donor cells)
Safety
Boxed warning: infusion reactions, GVHD, engraftment syndrome, graft failure.
FDA approval via BioSpace ↗
Blood & immune rebuildFDA-approved

RYONCIL

remestemcel-L-rknd

Steroid-refractory acute GVHD in children (2 months+)

70%overall response at day 28 (54 children)

Donor bone-marrow mesenchymal stromal cells in 54 children, 89% with grade C/D disease. 30% had complete and 41% partial responses by day 28.

Why it matters: The only FDA-approved MSC product, reached after rejections in 2020 and 2023 over potency assays.

Approved
Dec 18, 2024
Evidence
Single-arm
Cell source
Allogeneic (donor cells)
Safety
No boxed warning. Label warnings: hypersensitivity and infusion reactions, transmission of infectious agents, ectopic tissue formation.
FDA: RYONCIL prescribing information ↗
Blood & immune rebuildFDA-approved

HPC, Cord Blood (9 licensed banks)

HEMACORD, DUCORD, ALLOCORD, CLEVECORD, REGENECYTE and 4 more

Unrelated-donor transplant to rebuild blood and immune function

9public and commercial cord blood banks licensed

FDA licensed cord blood from New York Blood Center, ClinImmune, Duke, Cardinal Glennon, LifeSouth, Bloodworks, Cleveland, MD Anderson and StemCyte on existing transplant outcome data, without new trials.

Why it matters: The oldest licensed stem cell product class in the US, and the first commercial license (StemCyte) came only in 2024.

Approved
Nov 2011 (HEMACORD) to Nov 2024 (REGENECYTE)
Evidence
Legacy registry data
Cell source
Allogeneic (donor cells)
Safety
Boxed warning: fatal infusion reactions, GVHD, engraftment syndrome and graft failure.
FDA: cord blood products FAQ ↗
Blood & immune rebuildFDA-approved

RETHYMIC

allogeneic processed thymus tissue-agdc

Congenital athymia in children

77%survival at 1 year (76% at 2 years)

Children born without a thymus usually die by age 2–3. Across 105 children, implanted donor thymus gave 77% survival at 1 year, and 94% of 1-year survivors were alive at a median 10.7 years.

Why it matters: Dose is sized to each child's body surface area: early patient-customized tissue dosing.

Approved
Oct 8, 2021
Evidence
Natural-history control
Cell source
Allogeneic (donor cells)
Safety
Hypertension, cytokine release, rash, low platelets, GVHD.
Medthority: Rethymic approval data ↗
Engineered immune cellsFDA-approved

KYMRIAH

tisagenlecleucel

B-cell acute lymphoblastic leukemia (ALL) up to age 25; DLBCL; follicular lymphoma

83%remission within 3 months (63 patients, ELIANA)

The patient's own T cells engineered with a CD19 CAR. 83% of children and young adults with relapsed leukemia went into remission.

Why it matters: First CAR-T and first gene therapy approved in the US.

Approved
Aug 30, 2017 (first CAR-T)
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: cytokine release syndrome, neurotoxicity, secondary T-cell cancers.
NCI: tisagenlecleucel approval ↗
Engineered immune cellsFDA-approved

YESCARTA

axicabtagene ciloleucel

Large B-cell lymphoma (2nd line+); follicular lymphoma

8.3 vs 2.0 momedian event-free survival vs standard care (ZUMA-7, n=359)

In a randomized trial against standard chemotherapy and transplant, CAR-T cut the risk of an event by 60% (HR 0.40); response rate 83% vs 50%.

Why it matters: Moved CAR-T earlier in treatment by beating standard of care head-to-head.

Approved
Oct 18, 2017; 2nd line Apr 1, 2022
Evidence
Randomized
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: CRS (90%), neurotoxicity (78%), secondary T-cell cancers.
ASCO Post: axi-cel second-line approval ↗
Engineered immune cellsFDA-approved

TECARTUS

brexucabtagene autoleucel

Mantle cell lymphoma; adult B-cell acute lymphoblastic leukemia

87%response rate in mantle cell lymphoma (60 evaluable, ZUMA-2)

CD19 CAR-T for relapsed mantle cell lymphoma after BTK inhibitors: 62% complete remissions. The accelerated approval was converted to full approval in 2026. Also approved for adult acute lymphoblastic leukemia.

Why it matters: First CAR-T for mantle cell lymphoma.

Approved
Jul 24, 2020 (MCL, accelerated; full approval 2026); adult ALL later
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: CRS, neurotoxicity, secondary T-cell cancers.
ONS: FDA approves brexucabtagene autoleucel ↗
Engineered immune cellsFDA-approved

BREYANZI

lisocabtagene maraleucel

Large B-cell, follicular, mantle cell and marginal zone lymphoma; CLL/SLL

84.4%response rate in marginal zone lymphoma (77 patients)

A CD19 CAR-T with a defined CD8:CD4 mix, now approved across six B-cell cancers. In marginal zone lymphoma, 55.8% had complete responses.

Why it matters: Broadest CAR-T label: one product expanded through many single-indication trials.

Approved
Feb 5, 2021; marginal zone Dec 4, 2025
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: CRS, neurotoxicity, secondary T-cell cancers.
ASCO Post: liso-cel for marginal zone lymphoma ↗
Engineered immune cellsFDA-approved

ABECMA

idecabtagene vicleucel

Relapsed/refractory multiple myeloma

13.3 vs 4.4 momedian progression-free survival vs standard regimens (KarMMa-3)

First BCMA CAR-T. In 386 randomized patients, it more than doubled progression-free survival (HR 0.49); response 71% vs 42%.

Why it matters: First cell therapy for myeloma.

Approved
Mar 26, 2021; 3rd line Apr 4, 2024
Evidence
Randomized
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: CRS, neurotoxicity, HLH/MAS, prolonged low blood counts, secondary T-cell cancers.
ASCO Post: cilta-cel and ide-cel approvals ↗
Engineered immune cellsFDA-approved

CARVYKTI

ciltacabtagene autoleucel

Relapsed/refractory multiple myeloma (lenalidomide-refractory, 2nd line+)

HR 0.55risk of death vs standard care (CARTITUDE-4)

In 419 randomized patients, BCMA CAR-T cut progression risk by 71% (HR 0.29) and death risk by 45% at 33.6 months.

Why it matters: Clearest overall-survival benefit for any CAR-T.

Approved
Feb 28, 2022; 2nd line Apr 5, 2024
Evidence
Randomized
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: CRS, neurotoxicity incl. parkinsonism and Guillain-Barré, HLH, low blood counts, secondary cancers.
ASCO Post: CARTITUDE-4 updated analysis ↗
Engineered immune cellsFDA-approved

AUCATZYL

obecabtagene autoleucel

Adult relapsed/refractory B-cell acute lymphoblastic leukemia

42%complete remission within 3 months (27 of 65)

A CD19 CAR with a fast off-rate binder designed to lower toxicity; median remission lasted 14.1 months.

Why it matters: Shows CAR design can trade some potency for much lower toxicity.

Approved
Nov 8, 2024
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
Severe CRS only 3% and severe ICANS 7%; no REMS required.
ASCO Post: obe-cel approval ↗
Engineered immune cellsFDA-approved

AMTAGVI

lifileucel

Advanced melanoma after anti-PD-1 therapy

31.5%response rate (of 73 patients)

Tumor-infiltrating lymphocytes grown from the patient's own tumor. About 1 in 3 patients whose melanoma had failed immunotherapy responded, many durably.

Why it matters: First cell therapy for a solid tumor, made from the patient's own tumor.

Approved
Feb 16, 2024 (accelerated)
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: treatment-related death, prolonged cytopenia, severe infection, organ impairment.
FDA: lifileucel accelerated approval ↗
Engineered immune cellsFDA-approved

TECELRA

afamitresgene autoleucel

Metastatic synovial sarcoma (HLA-A*02, MAGE-A4 positive)

43.2%response rate (44 patients infused)

T cells engineered with a MAGE-A4 T-cell receptor. 39% of responders were still responding at 12 months.

Why it matters: First engineered TCR therapy: patient selection by HLA type is built into the label.

Approved
Aug 2, 2024 (accelerated)
Evidence
Single-arm
Cell source
Autologous (patient's own cells)
Safety
Boxed warning: serious or fatal cytokine release syndrome.
FDA: afami-cel accelerated approval ↗
Engineered immune cellsFDA-approved

PROVENGE

sipuleucel-T

Metastatic castration-resistant prostate cancer

25.8 vs 21.7 momedian overall survival vs placebo (IMPACT, n=512)

The patient's own antigen-presenting cells are activated and returned. It reduced risk of death by 22% (HR 0.78) without slowing measured progression.

Why it matters: First autologous cell therapy approved, and still the only one approved on an overall-survival endpoint.

Approved
Apr 29, 2010
Evidence
Randomized
Cell source
Autologous (patient's own cells)
Safety
Infusion reactions; no boxed warning reported.
NEJM IMPACT trial (PubMed) ↗
Tissue & organ repairFDA-approved

LANTIDRA

donislecel

Type 1 diabetes with repeated severe hypoglycemia (adults)

21 of 30insulin-free for a year or more

Donor pancreatic islets infused into the liver. 21 of 30 needed no insulin for at least a year, and 10 stayed insulin-free more than five years.

Why it matters: First cell therapy for type 1 diabetes and the precedent for stem-cell-derived islets.

Approved
Jun 28, 2023
Evidence
Single-arm
Cell source
Allogeneic (donor cells)
Safety
Lifelong immunosuppression; procedure risks.
BioSpace: first cell therapy for T1D ↗
Tissue & organ repairFDA-approved

ZEVASKYN

prademagene zamikeracel

Wounds in recessive dystrophic epidermolysis bullosa

81% vs 16%wounds 50%+ healed at 6 months, treated vs control

The patient's own skin cells are gene-corrected to make type VII collagen and grafted as sheets. 43 wound pairs were compared within the same patients.

Why it matters: A one-time, patient-specific surgical product with healing seen up to 8 years.

Approved
Apr 29, 2025
Evidence
Intrapatient control
Cell source
Autologous (patient's own cells)
Safety
No treatment-related serious adverse events.
Drugs.com: FDA approves Zevaskyn ↗
Tissue & organ repairFDA-approved

MACI

autologous cultured chondrocytes on porcine collagen membrane

Full-thickness knee cartilage defects (adults). Not approved for osteoarthritis or general knee arthritis

5 yearsbenefit sustained vs microfracture (128 of 144 followed)

The patient's own cartilage cells are grown on a membrane and implanted. In 144 randomized patients (72 per arm), KOOS pain rose from 37.0 to 82.5 with MACI, significantly more than with microfracture at 2 years.

Why it matters: One of the few cell products with a randomized surgical comparator and 5-year data.

Approved
Dec 2016
Evidence
Randomized
Cell source
Autologous (patient's own cells)
Safety
Joint pain, graft overgrowth; porcine/bovine allergy contraindication.
SUMMIT 5-year results (PubMed) ↗
Tissue & organ repairFDA-approved

STRATAGRAFT

allogeneic keratinocytes and fibroblasts in murine collagen

Deep partial-thickness thermal burns (adults)

96%of sites spared an autograft donor wound (68 of 71)

Lab-grown donor skin compared with the patient's own skin graft in the same patient. Durable wound closure at 3 months was 83% vs 86%.

Why it matters: Success defined practically: nearly as good as an autograft without a second wound.

Approved
Jun 2021
Evidence
Intrapatient control
Cell source
Allogeneic (donor cells)
Safety
Itching 11%; xenotransplant rules mean patients cannot donate blood or tissue.
FDA: StrataGraft label ↗
Tissue & organ repairFDA-approved

ENCELTO

revakinagene taroretcel-lwey

Macular telangiectasia type 2 (adults)

54.8%slower photoreceptor loss vs sham (trial 1; 30.6% in trial 2)

An encapsulated cell implant in the eye that releases CNTF. Two sham-controlled trials in 228 patients both met their 24-month endpoint.

Why it matters: First encapsulated-cell therapy approved; the capsule shields donor cells from the immune system.

Approved
Mar 2025
Evidence
Randomized
Cell source
Allogeneic (donor cells)
Safety
Delayed dark adaptation (~20%) and small pupils (~15%).
NEI: long-term benefit of implant ↗
Tissue & organ repairFDA-approved

SYMVESS

acellular tissue engineered vessel-tyod

Extremity arterial injury needing urgent bypass (adults)

84.3%vessels open at day 30 (43 of 51)

A vessel grown from donor cells and then decellularized. Amputation was 9.8% and graft infection 2% in trauma patients, compared with published synthetic-graft rates of 24.3% and 8.4%.

Why it matters: Cells as a manufacturing tool: the final product contains no living cells.

Approved
Dec 19, 2024
Evidence
Single-arm
Cell source
Allogeneic (donor cells)
Safety
Graft rupture and thrombosis warnings.
JAMA Surgery: V005 trial ↗
Tissue & organ repairFDA-approved

LAVIV

azficel-T

Moderate-to-severe nasolabial fold wrinkles (adults)

421patients in two randomized, placebo-controlled phase 3 trials

The patient's own cultured skin fibroblasts, injected in three sessions about five weeks apart. Approval followed a complete response letter and an added skin-biopsy safety study.

Why it matters: First personalized aesthetic cell therapy approved by FDA.

Approved
Jun 21, 2011
Evidence
Randomized
Cell source
Autologous (patient's own cells)
Safety
Injection-site reactions.
Fibrocell: FDA approval of LAVIV ↗
Tissue & organ repairFDA-approved

GINTUIT

allogeneic keratinocytes and fibroblasts in bovine collagen

Gum tissue repair in mucogingival surgery (adults)

≥50%of patients gained 2 mm+ of keratinized gum tissue

A donor-cell dressing that regrows gum tissue without harvesting tissue from the patient's palate. In each of two studies, at least half of patients gained 2 mm or more; 121 subjects in total.

Why it matters: First allogeneic cell product for dentistry.

Approved
Mar 9, 2012
Evidence
Intrapatient control
Cell source
Allogeneic (donor cells)
Safety
Sinusitis, mouth ulcers, local pain.
FDA press release (archived) ↗
Next wave (investigational)Investigational

Zimislecel (VX-880)

stem cell-derived islets (Vertex)

Type 1 diabetes with impaired hypoglycemia awareness

10 of 12insulin-free at one year (full dose)

Islets grown from pluripotent stem cells. In the Oct 2026 update all 12 had HbA1c below 7%, and time in target range rose from 49.5% to 93.3%.

Why it matters: A manufactured islet supply could end the donor-pancreas bottleneck.

Data
NEJM 2025; update Oct 2026
Evidence
Single-arm
Cell source
Allogeneic (donor cells)
Safety
Chronic immunosuppression; 2 deaths reported as unrelated. Phase 3 enrolling; no US filing confirmed.
MedCity: zimislecel results ↗
Next wave (investigational)Investigational

UP421 (Sana / Uppsala)

hypoimmune gene-edited donor islets

Type 1 diabetes, without immunosuppression

12 monthsislets evaded immune attack with no immunosuppressants (n=1)

Edited donor islets injected into muscle survived and made insulin with no anti-rejection drugs. Insulin output roughly halved between months 6 and 12; the low dose did not make the patient insulin-free.

Why it matters: The first human evidence that cells can be engineered to avoid rejection.

Data
First-in-human, 12-month data 2026
Evidence
Case series
Cell source
Allogeneic (donor cells)
Safety
No drug-related adverse events; durability unproven.
JDCA: Sana 1-year UP421 results ↗
Next wave (investigational)Investigational

Bemdaneprocel (BlueRock / Bayer)

embryonic stem cell-derived dopamine neuron progenitors

Parkinson's disease

−23 ptsMDS-UPDRS Part III OFF score, high dose (7 of 12 patients)

Twelve patients received grafts; there were no product-related serious adverse events or graft-induced dyskinesias, and the graft survived on PET. A sham-controlled phase 3 (exPDite-2) is enrolling.

Why it matters: Furthest-advanced pluripotent stem cell therapy for the brain in the US.

Data
Nature 2025; 36-month data 2026
Evidence
Single-arm
Cell source
Allogeneic (donor cells)
Safety
12 months of immunosuppression; RMAT designation.
Nature 2025: Phase I trial (PubMed) ↗
Next wave (investigational)Investigational

Amchepry (Kyoto CiRA / Sumitomo)

iPS cell-derived dopamine progenitors (raguneprocel)

Parkinson's disease

+35.7%motor score improvement ON medication at 24 months

Seven patients received reprogrammed-stem-cell neurons. Cells survived, produced dopamine and formed no tumors; 5 of 6 improved ON medication.

Why it matters: First iPS-cell therapy approved anywhere (conditionally, Japan).

Data
Nature Apr 2025; Japan conditional approval Mar 6, 2026
Evidence
Single-arm
Cell source
Allogeneic (donor cells)
Safety
Not FDA-approved; Japan approval is conditional on very small, uncontrolled data.
PMLive: Sumitomo limited approval in Japan ↗
Next wave (investigational)Investigational

Rezanecel (NRTX-1001, Neurona)

embryonic stem cell-derived inhibitory interneurons

Drug-resistant temporal lobe epilepsy

89%median seizure reduction (low-dose group)

A one-time implant of calming neurons. 7 of 9 low-dose patients halved their seizures at months 7–12.

Why it matters: A cell therapy aimed at restoring brain circuits rather than replacing lost cells.

Data
AAN 2026 data
Evidence
Single-arm
Cell source
Allogeneic (donor cells)
Safety
Company-reported, open-label. RMAT; sham-controlled Phase 3 starting 2H 2026.
Neurona AAN 2026 update ↗
Next wave (investigational)Investigational

CD19 CAR-T for autoimmune disease (Erlangen)

autologous CD19 CAR-T

Lupus, myositis, systemic sclerosis

15 of 15off all immunosuppressive drugs

All 8 lupus patients reached drug-free remission; myositis and systemic sclerosis patients also improved.

Why it matters: Points to an immune 'reset' for autoimmune disease.

Data
NEJM 2024; long-term series
Evidence
Case series
Cell source
Autologous (patient's own cells)
Safety
Mostly mild cytokine release; industry trials under way.
CGTLive: CAR-T in autoimmune disease ↗
Next wave (investigational)Investigational

HN2301 in vivo CAR-T (MagicRNA)

CAR mRNA in T-cell-targeted lipid nanoparticles

Lupus

5patients with B cells cleared, no cell manufacturing

CAR-T made inside the body from an infusion, with no cell collection or manufacturing. Lupus activity scores fell by up to 20 points at 3 months.

Why it matters: Could make customized cell therapy deliverable outside specialized centers.

Data
NEJM, Oct 2025
Evidence
Case series
Cell source
Autologous (patient's own cells)
Safety
No severe cytokine release; very early.
MagicRNA NEJM publication ↗
Next wave (investigational)Investigational

OpRegen (Lineage / Roche)

embryonic stem cell-derived retinal pigment epithelium

Geographic atrophy (dry AMD)

+6.2 lettersvision gain at 36 months (10 eyes)

Subretinal stem-cell-derived support cells; eyes with the most coverage gained 9.0 letters.

Why it matters: Durable vision gains from a one-time cell transplant.

Data
36-month data 2026
Evidence
Single-arm
Cell source
Allogeneic (donor cells)
Safety
Open-label; Phase 2a GAlette enrolling.
Retinal Physician: OpRegen ↗
Next wave (investigational)Investigational

HIV remission after stem cell transplant

allogeneic donor stem cells, mostly CCR5Δ32

HIV in people transplanted for blood cancer

~10people cured or in long-term remission

Berlin, London, Düsseldorf, City of Hope, New York, Geneva, Oslo and others. The Geneva case had no protective mutation.

Why it matters: Proof that replacing the immune system with stem cells can cure HIV.

Data
Case reports 2009–2026
Evidence
Case series
Cell source
Allogeneic (donor cells)
Safety
Not scalable: transplant is done only for cancer.
aidsmap: two more people may be cured ↗
Reading these figures: each number describes a trial population, not a promise for any single patient. Many approved products carry boxed warnings or restrictions, and investigational cases are not FDA approved (two are conditionally approved in Japan only). Every approved product is given in a transplant, oncology, surgical or specialty center. Figures were checked against FDA labels, FDA announcements or the primary publications on November 16, 2026; always confirm the current label on DailyMed before clinical use.